← Back to markets
Novavax
NVAX · Health Care · Biotechnology
$10.08-0.4%
RS +13.6
Returns
| 7D | +7.2% |
| 1M | +36.6% |
| 3M | -0.9% |
| 6M | +6.6% |
| YTD | +50.6% |
| 1Y | +35.5% |
About Novavax
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria.